Research.Patient.info
Late-onset Pompe Disease research hub
2 indexed studies · 2 currently recruiting
- recruitingPHASE1, PHASE2
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease
This study tests a new medicine called DNL952 for adults with late-onset Pompe disease. Pompe disease causes progressive muscle weakness. Researchers want to check the safety of DNL952, see how well the body tolerates different doses, and find out how the drug behaves inside the body.
United States · Germany · Netherlands - recruitingTherapeutic confirmatory (Phase III)
An Open-label Study of the Safety, Pharmacokinetics, Efficacy, Pharmacodynamics, and Immunogenicity of Cipaglucosidase Alfa/Miglustat in Pediatric Subjects Aged 0 to < 18 Years with Late-onset Pompe Disease
This study tests a two-part treatment called cipaglucosidase alfa and miglustat in children and teenagers with late-onset Pompe disease. Pompe disease weakens muscles over time. Researchers want to find out how safe the medicine is, how the body handles it, and if it helps improve muscle strength and breathing.
Italy · Germany